All News about Day One Biopharmaceuticals, Inc. - Common Stock
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_8099.png?width=1200&height=800&fit=crop)
Analyst Expectations for Day One Biopharmaceutical's Future
April 05, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/04/25/ge_healthcare_technologies_-_logo.jpg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 25, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/04/20/lam_research_-_logo.jpg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
Where Day One Biopharmaceutical Stands With Analysts
February 03, 2023
Via Benzinga
What 7 Analyst Ratings Have To Say About Day One Biopharmaceutical
January 09, 2023
Via Benzinga
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
Day One to Participate in the Cowen 43rd Annual Health Care Conference
February 27, 2023
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2022/12/14/dawn_logo_light__9c308943a89a754da8350168ab16d381.png?width=1200&height=800&fit=crop)
This Pediatric Cancer Company Makes It To Analyst's Conviction List
December 14, 2022
Via Benzinga
![](/next-assets/images/schema-image-default.png)
12 Health Care Stocks Moving In Thursday's After-Market Session
February 16, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023
February 08, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/01/09/dawn_logo_light__9c308943a89a754da8350168ab16d381.png?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_8593.png?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
December 05, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_30794.jpeg?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
December 01, 2022
Via Benzinga
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
![](https://ml.globenewswire.com/media/4b416a9e-66eb-4bda-aef9-e929b3c00eb9/small/dayonebio-logo-rgb-square-large-jpg.jpg)
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Exposures
COVID-19
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free